Armed malaria protein found to kill cancer cells

A new type of cancer therapy based on seemingly unrelated elements of malaria and cancer is showing promise for development. Kairos Therapeutics, a Vancouver-based biotech company spun-out of The Centre for Drug Research and Development (CDRD), has partnered with VAR2 Pharmaceuticals to advance the technology into clinical trials.

While looking into why pregnant women are particularly susceptible to malaria, researchers from the University of British Columbia, BC Cancer Agency, University of Copenhagen and VAR2 Pharmaceuticals discovered that the mosquito-borne parasite produces a protein "VAR2CSA" that binds to a particular type of sugar molecule found in the placenta. Further studies showed that the same sugar molecule is also found on the majority of cancer cell types. This commonality is understandable because both tumours and placentas share a number of characteristics, such as rapid growth and tissue invasion.

"I have worked for more than 25 years developing therapeutics for the treatment of cancer and I have never seen a target so broadly expressed on different forms of cancer as VAR2CSA," said John Babcook, President and CSO of Kairos Therapeutics.

John and a team of scientists at Kairos Therapeutics have developed a novel technology to arm antibodies and other targeting proteins with high potency toxins that could be used to specifically kill cancer cells. Kairos teamed up with scientists at VAR2 Pharmaceuticals, led by Drs. Mads Daugaard and Ali Salanti, and together they demonstrated that the sugar molecule could be a target for anti-cancer drugs, and that the VAR2CSA malarial protein could provide the tool for delivering Kairos' potent cancer killing toxins to tumours.

By attaching Kairos' novel toxins to VAR2CSA, the results showed that over 95 per cent of tumour cell lines were successfully treated across a broad array of cancer types, including pancreatic, brain, blood, ovarian, gastric, lung, bladder, skin, prostate, and breast.

The drug was then tested on mice that were implanted with human tumours. In models of non-Hodgkin's lymphoma, castration-resistant prostate cancer, and metastatic breast cancer, the Kairos-VAR2 therapeutic demonstrated the ability to prevent tumour growth, regress established tumours, and cure metastatic disease. The studies were published today in the journal Cancer Cell.

John was optimistic, "By arming VAR2CSA with Kairos' novel toxins, we have created a promising therapeutic that could benefit patients across multiple types of cancer".

Based on this work, Kairos Therapeutics and VAR2 Pharmaceuticals are now developing the compound for clinical trials in humans.

About Kairos Therapeutics Inc
Kairos Therapeutics is a biopharmaceutical company with a proprietary next-generation antibody-drug conjugate platform based on novel toxin, linker, and site-specific conjugation technology. Through key partnerships, Kairos is developing a pipeline of antibody-drug conjugate therapeutics for the treatment of various forms of cancer.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...